Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Astech Projects Comes of Age at 18 Years Old

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Astech celebrates milestone by offering free consultations and proposal of their turnkey approach to automation.

Astech was started with the founders’ vision to be “recognised as one of the world’s best” in the design and supply of custom robotics and automation for use in advanced manufacturing industries including pharmaceutical, medical device, consumer healthcare, petro-chemical and chemical. This has largely been achieved by providing the very best automation solutions tailored to customer’s unique and individual requirements.

Having gone from strength to strength with an increasing sized workforce, two relocations to larger premises and a Queen’s Award for Enterprise: Innovation, Astech Director, Anthony Moran commented “This is a significant milestone for us and we hope it reinforces our reputation for quality and longevity. We have ambitious plans to broaden our product portfolio and to keep offering valuable solutions to our customers”. He continued: "We are committed to being ‘best in class’ and if we continue to improve we can only become even more successful.  In addition to thanking our dedicated Astech team for all their hard work and commitment over the last 18 years we would like to thank our many clients that have entrusted Astech to provide them with innovative and intelligent design solutions”
 
To celebrate their anniversary Astech are currently offering a free consultation and proposal of their novel turnkey approach to automation which can consist of four key steps: (1) consultation & proposal, (2) concept design study, (3) proof of concept(s) and (4) detailed design, manufacture and testing. Simply complete the online form and one of Astech’s specialist Business Development Mangers will contact you.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!